Expression of Tight Junction Protein Claudin-4 in Basal-Like Breast Carcinomas

Claudins (CLDN) are tight junction proteins which contribute to the paracellular transport and ionic permeability of various epithelia. In recent years they came into focus for their suggested role in carcinogenesis and possible role in cancer therapy. According to our previous studies, in breast tissue CLDN4 is also related to the level of cellular differentiation. Thirty-eight estrogen (ER) and progesterone receptor (PgR) negative, HER2/neu negative, but cytokeratin 5/6 positive basal-like—mainly grade 3—breast carcinomas were compared with twenty-one grade 1, twenty-five grade 2 and twenty grade 3 non-basal-like invasive breast carcinomas, in respect to their CLDN4 expression. The immunohistochemical reactions were evaluated both semiquantitatively and by morphometrical analysis. Statistically significant difference (p = 0.001) was observable regarding CLDN4 expression in the basal-like group as compared to grade 1 and 2 cancers. Further, CLDN4 expression was significantly higher (p = 0.017) in the basal-like compared with the non-basal-like grade 3 carcinomas. Our results suggest that basal-like carcinomas are a subset of breast cancer with high level of CLDN4 protein expression. The finding is in accordance with our former observation that CLDN4 is indeed related to cellular differentiation. This observation may be seen as a further proof that basal-like carcinomas represent a separable group amongst grade 3 breast carcinomas.

[1]  A. Tőkés,et al.  Correction: Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study , 2005, Breast Cancer Research.

[2]  Takeshi Iwamura,et al.  Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer. , 2003, Cancer research.

[3]  M. Löhr,et al.  Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. , 2001, Gastroenterology.

[4]  H Buerger,et al.  Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes , 1999, The Journal of pathology.

[5]  Kazushi Fujimoto,et al.  Claudin-1 and -2: Novel Integral Membrane Proteins Localizing at Tight Junctions with No Sequence Similarity to Occludin , 1998, The Journal of cell biology.

[6]  A. Tőkés,et al.  The expression of five different claudins in invasive breast carcinomas: comparison of pT1pN1 and pT1pN0 tumors. , 2005, Pathology, research and practice.

[7]  N. Udvarhelyi,et al.  Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma. , 2006, Gynecologic oncology.

[8]  A. Kiss,et al.  Increased expression of claudins in cervical squamous intraepithelial neoplasia and invasive carcinoma. , 2005, Human pathology.

[9]  A. Nobel,et al.  The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.

[10]  Therese Sørlie,et al.  Molecular classification of breast tumors: toward improved diagnostics and treatments. , 2007, Methods in molecular biology.

[11]  S. Lakhani,et al.  Demystifying basal-like breast carcinomas , 2006, Journal of Clinical Pathology.

[12]  S. Schnitt,et al.  Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer , 2006, Modern Pathology.

[13]  P. Bonnier,et al.  Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. , 2007, Human pathology.

[14]  C. Perou,et al.  Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma , 2006, Modern Pathology.

[15]  D. Easton,et al.  Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival , 2007, Breast Cancer Research.

[16]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[17]  A. Ashworth,et al.  Basal-like breast carcinomas: clinical outcome and response to chemotherapy , 2006, Journal of Clinical Pathology.